Back to results
US 2014/0234389 A1Published application
Sustained drug delivery implant
AssigneeAllergan, Inc.
InventorsJane-Guo Shiah, Chetan Pujara
Life of this patent
Estimating the term…
Abstract
Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
Claims7
An intraocular implant for the treatment of a posterior ocular condition in a human patient comprising:
- a biodegradable polymer matrix comprising at least one biodegradable polymer;
- and
- a brimonidine free base agent;
- wherein the implant is configured to deliver the brimonidine free base agent to the vitreous of an eye of a patient suffering from a posterior ocular condition for a brimonidine free base agent delivery duration of up to six months and wherein the biodegradable polymer matrix is configured to completely or almost completely degrade, once placed into the vitreous of the eye, within a period of time of about two times the brimonidine free base agent delivery duration or less.
1 more element
Dependencies are inferred from the claim text.